Vancomycin toxicity: a prospective study

Area of Science:

• Pharmacology
• Nephrology
• Ototoxicology

Background:

• Intravenous vancomycin is a critical antibiotic for serious Gram-positive infections.
• Assessing vancomycin's toxicity profile, especially in combination with other nephrotoxic agents like aminoglycosides, is crucial for patient safety.

Purpose of the Study:

• To evaluate the toxicity of intravenous vancomycin in a prospective patient cohort.
• To specifically assess ototoxicity (hearing loss, tinnitus, dizziness) and nephrotoxicity (renal function decline).
• To investigate potential synergistic toxicity between vancomycin and concurrent or sequential aminoglycoside administration.

Main Methods:

• Prospective study design involving 34 patients receiving 39 courses of intravenous vancomycin.
• Categorization of vancomycin administration: alone or in combination with aminoglycosides.
• Monitoring for adverse events including hearing impairment and changes in renal function.

Main Results:

• Hearing loss was infrequent and mild, with patients often unaware.
• Two patients experienced transient tinnitus and dizziness, resolving upon vancomycin withdrawal.
• Renal function deterioration occurred in 7% during and 9% after vancomycin therapy, often associated with severe underlying conditions.
• No evidence of increased toxicity when vancomycin was combined with aminoglycosides.

Conclusions:

• Intravenous vancomycin exhibits a generally favorable toxicity profile regarding ototoxicity and nephrotoxicity in this cohort.
• The severity of underlying illness appears to be a significant factor in vancomycin-associated renal function decline.
• Vancomycin can be safely administered with aminoglycosides without apparent synergistic toxicity.